Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ELX/TEZ/IVA use in cystic fibrosis liver disease: Is the perspective of improved lung function worth the risk?

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Sept 2022

Gardiner A, Volovets A, Haber P, Jo H, Visser S, Yozghatlian V, Taylor N, Nolan S, Dentice R, Malouf M, Marinelli T, Sivam D

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles
Share to Cystic Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Liver Diseases

Share to Mutation

Source

Identifiers

PMID: 35760705
DOI: 10.1016/j.jcf.2022.06.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ELX/TEZ/IVA use in cystic fibrosis liver disease: Is the perspective of improved lung function worth the risk?PMID 35760705Read ↗

Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.Semantic proximity Read ↗

Real Life With Tezacaftor and Ivacaftor in Adult Patients With Cystic Fibrosis: Spanish Multicenter Study.Semantic proximity Read ↗

Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutationSemantic proximity Read ↗

Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.Semantic proximity Read ↗

The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France.Semantic proximity Read ↗

Cystic fibrosis: Does it matter to avoid crushing Elexacaftor/Tezacaftor/Ivacaftor (ETI) tablets?Semantic proximity Read ↗

Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.Semantic proximity Read ↗

SIMPLIFYing cystic fibrosis treatment in a post-modulator era.Semantic proximity Read ↗

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialSemantic proximity Read ↗

Improvement in sinonasal quality-of-life indicators for pediatric patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.Semantic proximity Read ↗

The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.Semantic proximity Read ↗

Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.